Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NNJ
|
|||
| Former ID |
DNC011938
|
|||
| Drug Name |
ZANOTERONE
|
|||
| Synonyms |
ZANOTERONE; 107000-34-0; UNII-XQ5V1W49JG; XQ5V1W49JG; WIN-49596; Zanoterone [USAN:INN]; Win 49,596; Zanoterone (USAN/INN); win49596; SCHEMBL60980; CHEMBL1908363; DTXSID50147873; BDBM50368314; 1'-(Methylsulfonyl)-1'H-5alpha,17alpha-pregn-20-yno(3,2-c)pyrazol-17-ol; D06357; 34004-EP2305642A2; 34004-EP2298765A1; 34004-EP2275420A1; 34004-EP2311453A1; 34004-EP2298764A1; 34004-EP2298748A2; 34004-EP2295416A2; 34004-EP2295055A2; 1'H-Pregn-20-yno(3,2-c)pyrazol-17-ol, 1'-(methylsulfonyl)-, (5alpha,17alpha)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate hyperplasia [ICD-11: GA90; ICD-10: N40] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N2O3S
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2(C#C)O)CCC4C3(CC5=CN(N=C5C4)S(=O)(=O)C)C
|
|||
| InChI |
1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
|
|||
| InChIKey |
MHDDZDPNIDVLNK-ZGIWMXSJSA-N
|
|||
| CAS Number |
CAS 107000-34-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002570) | |||
| REF 2 | Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.